# Swollen Knee Treatment Market > Swollen Knee Treatment Market By Type (Medications- Corticosteroids, Patient-controlled analgesia pumps, Surgery- Arthrocentesis, Arthroscopy, Knee replacement, and Others), End-User (Hospitals, Clinics, and Others) -Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.56% - **2024:** $ 1.35 Billion - **2025:** $ 1.42 Billion - **2035:** $ 2.45 Billion - **Key Players:** Johnson & Johnson (US), Pfizer (US), Bayer (DE), Novartis (CH), AbbVie (US), GlaxoSmithKline (GB), Sanofi (FR), Amgen (US), Merck & Co. (US) **Report ID:** MRFR/Pharma/4945-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/swollen-knee-treatment-market-6406 --- ## Market Summary ## **Swollen Knee Treatment Market Overview** Swollen Knee Treatment Market Size was valued at USD 1.28 Billion in 2023. The Global Swollen Knee Treatment industry is projected to grow from USD 1.35 Billion in 2024 to USD 2.12 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.93% during the forecast period (2024 - 2032). Nobody must sacrifice their preferred pastime or struggle daily because of chronic knee pain in July 2023. Kneeflow is being launched, a three-in-one massager that can be used by anyone who suffers from knee pain and mobility issues. It is a personal home massage tool for relief, prevention, and recovery from knee surgery, as well as any tenderness experienced after exercise. The symptoms of chronic knee pain typically include discomfort, stiffness, inflammation, and joint degradation. Pharmaceutical relief for pain therapies, physical therapy, steroid shots, and surgery are some of the options that patients often resort to; they are costly remedies that do not stop an ongoing degeneration of joint tissues. Kneeflow has a touch screen LCD (Liquid Crystal Display), which is simple to use with the compact size that makes it portable, and alongside this, it’s cordless. **The Endo International plc (NASDAQ: ENDP) on June 30th, 2022,** indicates that a subsidiary, Endo Ventures Limited (EVL), has completed a deal with Taiwan Liposome Company Ltd (TLC) to commercialize TLC599, which is an investigational product of TLC.TLC599 is a combination therapy currently in Phase 3 development as an injectable for the treatment of osteoarthritis knee pain. The agreement states that the major role of EVL will be regulatory approval, while product development will be left mainly to TLC and marketing in the United States. Endo is expected to distribute the product exclusively upon approval by the relevant regulatory authorities. In August 2019, Bioventus, a global leader in orthobiologic solutions, announced plans to introduce DUROLANE SJ(1mL) and received extended recommendations on DUROLANE(3mL), its single-shot jointfluid osteoarthritis (OA)treatment in Australia and New Zealand. Both are hyaluronic acid (HA)--based products and are available from LMT Surgical. In general, DUROLANE SJ (1mL) has been cleared by the Therapeutic Goods Administration (TGA)of Australia and MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, and it will launch later this year. It should only be used for relieving mild to moderate OA-associated pains in the ankle, elbow, wrist, fingers, and toes. Also, DUROLANE SJ(1mL) is indicated for postoperative pain following joint arthroscopy due to joint arthritis up until three months after surgery. Knee swelling or occasionally mentioned as “water on the knee” is a condition where excess fluid gets accumulated in an around the knee joint. This conditions in medical terms are referred to as “knee effusion”. The swollen knee can result due to injuries such as torn ligament, cartilage tear or broken bones. The increasing number of geriatric populations followed by the rising frequency of musculoskeletal diseases, a growing number of surgeries undertaken is projected to grow the swollen knee treatment market. The operating procedure of knee replacement is inclusive of various steps taken to implant the artificial device and replacement of the damaged knee. The swollen knee treatment market is anticipated to grow due to several factors such as the growing rate of elderly aged diseases like obesity, arthritis, osteoporosis, diabetes and sports-related injuries. Contrary, due to existing and upcoming advance technologies such as minimally invasive surgery and improved implant supplies are making it more broadly accepted even by the younger population. In spite of being a widely used technique for curing extremely debilitating diseases, such as rheumatoid arthritis, the swollen knee treatment market is confronting some challenges such as financial slowdown which is avoiding the growth of the market. Other growth restraining factors of the swollen knee treatment market are intense competition, huge surgical cost, growing awareness for some non-surgical treatment methods such as exercises, shoe inserts, walking aids, weight loss programs, and [painkiller](../../../reports/painkiller-market-19188) medicines. ## **Swollen Knee Treatment Market Segmentation** The swollen knee treatment market has been segmented on the basis of type and end-users. On the basis of type, the market has been classified as medications, patient-controlled analgesia (PCA) pumps, nerve blocks, liposomal bupivacaine, and surgery. The medications have been segmented into opioids and corticosteroids and others. The surgery is segmented into arthrocentesis, arthroscopy and knee replacement. The knee replacement is further segmented into total knee replacement, unicompartmental knee replacement, and others. On the basis of end-users, the market has been classified as hospitals, clinics, ambulatory surgery centers, and others. On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada. The European swollen knee treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The swollen knee treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The swollen knee treatment market in the Middle East and Africa has been segmented into the Middle East and Africa. In the swollen knee treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and due to favorable compensation setting for many surgical procedures. The European market is expected to hold the second largest market share. The market growth in this region can be attributed to the rising frequency of diabetes patients, increasing number of surgeries, and increasing demand for advanced treatment procedures are boosting the European market. The market share in Asia-Pacific is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increase in disposable income, and rising medical tourism. The market in the Middle East and Africa is expected to account for the smallest share of the swollen knee treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities. **Key Players** ### **Swollen Knee Treatment Market, by Type** ### **Swollen Knee Treatment Market, by End-User** ### **Swollen Knee Treatment Market, by Region** **Intended Audience** ## Market Drivers ### Rising Awareness of Knee Health There is a notable increase in public awareness regarding knee health and the implications of untreated knee conditions, which serves as a significant driver for the Swollen Knee Treatment Market. Educational campaigns and health initiatives aimed at promoting joint health have led to a greater understanding of the importance of early intervention. This heightened awareness encourages individuals experiencing knee swelling to seek medical advice sooner, thereby increasing the patient pool for treatment options. Furthermore, the proliferation of online health resources and community support groups has empowered patients to take proactive steps in managing their knee health. As awareness continues to grow, the Swollen Knee Treatment Market is poised for expansion, with more individuals actively pursuing treatment for swollen knees. ### Advancements in Treatment Technologies Technological innovations in the field of orthopedics and rehabilitation are transforming the Swollen Knee Treatment Market. The introduction of minimally invasive surgical techniques, such as arthroscopy, has revolutionized the approach to treating swollen knees, allowing for quicker recovery times and reduced hospital stays. Additionally, advancements in [regenerative medicine](https://www.marketresearchfuture.com/reports/regenerative-medicine-market-2220), including [stem cell therapy](https://www.marketresearchfuture.com/reports/stem-cell-therapy-market-6422) and platelet-rich plasma (PRP) treatments, are gaining traction as viable options for knee treatment. These technologies not only enhance treatment efficacy but also improve patient outcomes, thereby driving market growth. As healthcare providers increasingly adopt these advanced treatment modalities, the Swollen Knee Treatment Market is likely to witness a surge in demand for innovative solutions that address knee swelling and associated disorders. ### Aging Population and Lifestyle Changes The demographic shift towards an aging population is a critical factor influencing the Swollen Knee Treatment Market. As individuals age, the likelihood of developing knee-related issues increases, leading to a higher demand for treatment options. Additionally, lifestyle changes, such as increased sedentary behavior and obesity, exacerbate the prevalence of knee disorders. Data indicates that nearly 40% of adults aged 65 and older experience knee pain, highlighting the urgent need for effective treatment solutions. This demographic trend is prompting healthcare systems to adapt and expand their offerings in the Swollen Knee Treatment Market, ensuring that appropriate care is available for the growing number of affected individuals. Consequently, the market is expected to experience sustained growth as treatment options evolve to meet the needs of this aging population. ### Increasing Prevalence of Knee Disorders The rising incidence of knee disorders, including osteoarthritis and rheumatoid arthritis, is a primary driver of the Swollen Knee Treatment Market. According to recent data, approximately 30 million adults in the United States are affected by osteoarthritis, leading to a significant demand for effective treatment options. This trend is mirrored in various regions, where aging populations and sedentary lifestyles contribute to the prevalence of knee-related ailments. As more individuals seek medical intervention for swollen knees, the market for treatment options, including medications, physical therapy, and surgical procedures, is expected to expand. The growing awareness of knee health and the importance of timely treatment further fuels this demand, indicating a robust growth trajectory for the Swollen Knee Treatment Market. ### Integration of Holistic Treatment Approaches The shift towards holistic treatment approaches in healthcare is emerging as a significant driver for the Swollen Knee Treatment Market. Patients increasingly seek comprehensive care that addresses not only the physical aspects of knee swelling but also the psychological and emotional components. This trend has led to the incorporation of complementary therapies, such as acupuncture, massage therapy, and nutritional counseling, alongside conventional medical treatments. Research suggests that patients who engage in holistic care often report improved outcomes and satisfaction levels. As healthcare providers recognize the value of integrating these approaches, the Swollen Knee Treatment Market is likely to expand, offering a wider array of treatment options that cater to the diverse needs of patients experiencing swollen knees. ## Future Outlook The Swollen Knee Treatment Market is projected to grow at a 5.56% CAGR from 2025 to 2035, driven by increasing prevalence of knee disorders, advancements in treatment technologies, and rising healthcare expenditure. **New opportunities:** - Development of telehealth platforms for remote consultations and follow-ups. - Investment in regenerative medicine techniques for knee treatment. - Expansion of personalized treatment plans using AI-driven analytics. By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment methodologies and increased patient demand. ## Segment Insights ### By Type: Medications (Largest) vs. Surgery (Fastest-Growing) In the Swollen Knee Treatment Market, medications dominate the segment, holding the largest market share due to their widespread acceptance and effectiveness in managing pain and inflammation. Patient-controlled analgesia (PCA) pumps and nerve blocks follow, offering targeted relief and convenience, while newer options like liposomal bupivacaine represent an innovative addition. Surgery, although traditionally seen as a last resort, is increasingly being embraced as a viable treatment option, particularly for chronic conditions where other treatments have failed to provide relief, contributing to its growth in market share. The growth trends in this segment are driven by advancements in medical technology and an increasing understanding of pain management. Medications remain crucial for acute treatment, yet surgeries are gaining traction due to their long-term efficacy for certain patients. Factors such as rising healthcare spending, the aging population, and a greater emphasis on patient-centric care are also paving the way for surgery to emerge as a favored treatment choice, while innovations in medication formulations continue to enhance their appeal as primary interventions. Medications (Dominant) vs. Surgery (Emerging) Medications for swollen knee treatment, such as non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, have established themselves as the dominant approach due to their accessibility and ability to provide immediate relief. These treatments are commonly prescribed and trusted, which adds to their robust position in the market. On the other hand, surgery, including arthroscopy and knee [joint replacement](https://www.marketresearchfuture.com/reports/joint-replacement-market-43209), is emerging as a crucial option for patients who do not respond to conservative treatment. The surgical segment is characterized by rapid advancements in minimally invasive techniques, which increase recovery rates and reduce hospital stays, thus driving patient preference and adoption. As more patients seek long-term solutions for chronic knee conditions, surgery's role in the treatment landscape is set to expand significantly. ### By End-User: Hospitals (Largest) vs. Clinics (Fastest-Growing) In the Swollen Knee Treatment Market, hospitals hold the largest share among the end-user segments, attributed to their advanced facilities and comprehensive treatment options. Clinics also represent a significant portion of the market, serving those seeking outpatient care. The presence of specialized orthopedic clinics is enhancing competition and diversifying treatment choices. The growth trends indicate a rise in demand for knee treatment services in ambulatory surgery centers and clinics, driven by increased health awareness and accessible healthcare options. Patients favor these centers due to quicker recovery times and lesser costs. An aging population and rising incidences of sports injuries further contribute to the growth of these segments. Hospitals (Dominant) vs. Ambulatory Surgery Centers (Emerging) Hospitals remain the dominant end-user in the Swollen Knee Treatment Market, offering comprehensive surgical and non-surgical treatment options with advanced technology and a multidisciplinary approach. They cater to a wide patient demographic, thus capturing a large market share. Alternatively, ambulatory surgery centers are emerging as a preferred option for many patients due to their cost-effectiveness and convenience. These centers provide same-day discharge, which appeals to patients wanting to avoid lengthy hospital stays. The growth of ambulatory centers is fueled by an increase in minimally invasive procedures, patient preference for outpatient care, and strategic partnerships with healthcare providers, positioning them for robust growth in the coming years. ## Regional Market Share Analysis ### North America : Healthcare Innovation Leader North America is the largest market for swollen knee treatments, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high disposable incomes, and a growing aging population, which drives demand for effective treatment options. Regulatory support from agencies like the FDA further catalyzes market growth by expediting the approval of new therapies and technologies. The United States is the leading country in this market, with major players like Johnson & Johnson, Pfizer, and AbbVie dominating the landscape. The competitive environment is characterized by continuous innovation and strategic partnerships among key players. Canada also contributes significantly, focusing on improving healthcare access and treatment options for knee-related ailments, thereby enhancing market dynamics. ### Europe : Emerging Market with Regulations Europe is the second-largest market for swollen knee treatments, accounting for about 30% of the global market share. The region's growth is driven by increasing awareness of knee health, advancements in medical technology, and supportive regulatory frameworks from the European Medicines Agency (EMA). Countries are also focusing on improving healthcare systems, which enhances patient access to innovative treatments. Germany, France, and the UK are the leading countries in this market, with a strong presence of key players like Bayer and Novartis. The competitive landscape is marked by a mix of established pharmaceutical companies and emerging biotech firms, all striving to meet the growing demand for effective knee treatments. The emphasis on research and development is evident, as companies aim to introduce novel therapies to address various knee conditions. ### Asia-Pacific : Rapidly Growing Healthcare Sector Asia-Pacific is witnessing rapid growth in the swollen knee treatment market, holding approximately 20% of the global market share. The region's expansion is fueled by increasing healthcare expenditure, a rising geriatric population, and growing awareness of knee health. Countries like China and India are investing heavily in healthcare infrastructure, which is expected to further boost market demand in the coming years. China is the largest market in the region, followed by India and Japan. The competitive landscape is evolving, with both local and international players vying for market share. Key companies are focusing on strategic collaborations and product innovations to cater to the diverse needs of patients. The presence of major pharmaceutical firms is also enhancing the availability of effective treatment options across the region. ### Middle East and Africa : Untapped Market Potential The Middle East and Africa represent an emerging market for swollen knee treatments, holding about 5% of the global market share. The region's growth is driven by increasing healthcare investments, rising awareness of knee-related health issues, and a growing population. Governments are focusing on improving healthcare access and quality, which is expected to enhance market dynamics in the coming years. Countries like South Africa and the UAE are leading the market, with a growing presence of both local and international pharmaceutical companies. The competitive landscape is characterized by a mix of established players and new entrants, all aiming to provide innovative treatment solutions. The region's unique challenges, such as varying healthcare standards, present opportunities for companies to introduce tailored solutions to meet local needs. ## Competitive Benchmarking The Swollen Knee Treatment Market is characterized by a dynamic competitive landscape, driven by an increasing prevalence of knee-related disorders and a growing demand for effective treatment options. Major players such as Johnson & Johnson (US), Pfizer (US), and AbbVie (US) are strategically positioned to leverage their extensive research and development capabilities, focusing on innovative therapies and advanced treatment modalities. These companies are actively engaged in partnerships and collaborations to enhance their product offerings, thereby shaping a competitive environment that emphasizes both efficacy and patient-centric solutions. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency and reduce costs. The market appears moderately fragmented, with a mix of established pharmaceutical giants and emerging players. This structure allows for a diverse range of treatment options, although the influence of key players remains significant in setting industry standards and driving innovation. In August 2025, Johnson & Johnson (US) announced the launch of a new biologic therapy aimed at reducing inflammation in patients with knee osteoarthritis. This strategic move is likely to enhance their market share by addressing unmet medical needs and providing a novel treatment option that could improve patient outcomes. The introduction of this therapy underscores the company's commitment to innovation and its focus on expanding its portfolio in the knee treatment segment. Similarly, in July 2025, AbbVie (US) expanded its clinical trials for a new injectable treatment designed to alleviate pain associated with knee injuries. This expansion not only reflects AbbVie's dedication to advancing its research pipeline but also positions the company to capture a larger share of the market as it seeks to provide effective solutions for patients suffering from knee-related ailments. The strategic importance of this initiative lies in its potential to establish AbbVie as a leader in the treatment of knee conditions. Moreover, in September 2025, Pfizer (US) entered into a strategic partnership with a biotechnology firm to co-develop a novel gene therapy targeting knee cartilage regeneration. This collaboration is indicative of Pfizer's forward-thinking approach and its willingness to invest in cutting-edge technologies that could redefine treatment paradigms in the swollen knee treatment market. The implications of this partnership may extend beyond immediate product development, potentially influencing future research directions and therapeutic strategies. As of October 2025, current competitive trends in the Swollen Knee Treatment Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are becoming more prevalent, fostering innovation and enhancing the ability of companies to respond to evolving patient needs. Looking ahead, competitive differentiation is likely to shift from traditional price-based competition to a focus on innovation, technological advancements, and the reliability of supply chains, thereby reshaping the landscape of knee treatment solutions. ## Report Scope | MARKET SIZE 2024 | 1.35(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 1.425(USD Billion) | | MARKET SIZE 2035 | 2.448(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.56% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Johnson & Johnson (US), Pfizer (US), Bayer (DE), Novartis (CH), AbbVie (US), GlaxoSmithKline (GB), Sanofi (FR), Amgen (US), Merck & Co. (US) | | Segments Covered | Type | | Key Market Opportunities | Integration of telehealth solutions enhances access to Swollen Knee Treatment Market services. | | Key Market Dynamics | Rising demand for minimally invasive procedures drives innovation in swollen knee treatment options and competitive market dynamics. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current market valuation of the Swollen Knee Treatment Market?** A: The market valuation of the Swollen Knee Treatment Market was 1.35 USD Billion in 2024. **Q: What is the projected market size for the Swollen Knee Treatment Market by 2035?** A: The projected market size for the Swollen Knee Treatment Market is 2.448 USD Billion by 2035. **Q: What is the expected CAGR for the Swollen Knee Treatment Market during the forecast period?** A: The expected CAGR for the Swollen Knee Treatment Market from 2025 to 2035 is 5.56%. **Q: Which companies are the key players in the Swollen Knee Treatment Market?** A: Key players in the Swollen Knee Treatment Market include Johnson & Johnson, Pfizer, Bayer, Novartis, AbbVie, GlaxoSmithKline, Sanofi, Amgen, and Merck & Co. **Q: What are the main treatment types in the Swollen Knee Treatment Market?** A: Main treatment types in the market include medications, patient-controlled analgesia (PCA) pumps, nerve blocks, liposomal bupivacaine, and surgery. **Q: How much revenue did medications generate in the Swollen Knee Treatment Market in 2024?** A: Medications generated approximately 0.54 USD Billion in revenue in the Swollen Knee Treatment Market in 2024. **Q: What is the revenue projection for patient-controlled analgesia (PCA) pumps by 2035?** A: The revenue projection for patient-controlled analgesia (PCA) pumps is expected to reach 0.49 USD Billion by 2035. **Q: Which end-user segments are included in the Swollen Knee Treatment Market?** A: End-user segments in the market include hospitals, clinics, ambulatory surgery centers, and others. **Q: What was the revenue generated by hospitals in the Swollen Knee Treatment Market in 2024?** A: Hospitals generated approximately 0.54 USD Billion in revenue in the Swollen Knee Treatment Market in 2024. **Q: What is the expected growth trend for the Swollen Knee Treatment Market from 2025 to 2035?** A: The Swollen Knee Treatment Market is expected to experience a growth trend, reaching 2.448 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/swollen-knee-treatment-market-6406*